Let's start with this fascinating news from the FDA. First of all, already in July, we announced the positive feedback from the FDA regarding the clinical development plan registration for Bexmarilimab, or Bex as we call it, for the treatment of high-risk myelodysplastic syndromes (MDS). In a nutshell, this means that only one randomized Phase 3 trial is required from us to gain approval. This week, on Monday, we had a recent press release about the FDA's latest decision, granting Fast Track Designation for the treatment of relapsed or refractory myelodysplastic syndromes (r/r MDS) in combination with acetaldehyde. And, as you can see from the bullet points, this is what it signifies. In practice, it means more frequent meetings with the FDA to discuss the development path and plan, to ensure correct collection of data needed for the full approval. And also, it means eligibility for accelerated approval. And prior to the review, if relevant criteria are met. And what are these relevant criteria? There is an unmet medical need for the disease. It is a serious and important disease that lacks suitable treatments. And we need to remember that when we're talking about relapsed MDS. So the current overall survival with the current agents. So it's around six to seven months in median. And it means that it's a number that we see as an overall figure in metastatic pancreatic cancer. So it's a deadly disease. But then let's move forward, after this exciting FDA news, how does H2 look? And then, what can you expect to see from us next? First of all, we will have an R&D day and provide further market guidance on vaccine maps and the cancer development plan, as well as an update on the ongoing Phase 2 survival data. In October 2024. Unfortunately, I cannot at this stage tell you the exact date. But anyway, in October. In October, so you won't need to wait a long time. When we open up our R&D pipeline. Then, about the next Mab—MDS recruitment status. So, it's running, it's enrolling, it's enrolling. Recruitment is projected to be completed by the end of the year or by the end of Q4 2024, followed by major future releases of the results. So, they will be at the medical congresses, as is typical in the industry. The current plan is that the next data release, from Basemap, will involve new patients. So that will be at the ASH meeting, the American Society of Hematology meeting taking place in December, and then thereafter. The next one will be next June at ASCO, the American Society of Clinical Oncology Annual Meeting, or the European Hematology Association meeting. So, those are the time points where you can expect to get more data, for example, from the response rates and duration of responses and so on. So we transition to what is considered a standard rhythm of reporting scientific results from enrolling in clinical trials. I'm really happy to announce that in solid tumors, we are also making progress with the pipeline, specifically, our first PD-1 inhibitor combination trial. So, the preparations have been initiated, and this will be the first trial to examine the safety and, of course, also the preliminary efficacy of Bexmarilimab's PD1 inhibitor combo or Bexmarilimab's checkpoint inhibitor combination. And the first trial site. It will be at the Royal Marsden Hospital in London, UK, but there will be more about the development plan in solid tumors in October during the R&D day.